FRNM

9.3605.69%
AE

Aaron Elliott

CEO & Director

Mr. Aaron Elliott, Ph.D., is Chief Executive Officer of Freenome, Inc. from April 1, 2025 and has been its Director since April 2025. Mr. Elliott has Pst Dc Trn in Genetics from Jefferson (Philadelphia University + Thomas Jefferson University). Mr. Elliott has B.S. in Biology from Franklin & Marshall College. Mr. Elliott has Pst Dc Trn in Genetics from Johns Hopkins School of Medicine. He has been Chief Executive Officer of REALM IDx, Inc. (formerly known as Konica Minolta Precision Medicine, Inc.). since May 4, 2021. In his new role, Elliott is responsible for driving execution across all KMPM business units, which include Ambry Genetics, Invicro and KMPM-Japan. Elliott served as Interim Chief Scientific Officer at Ambry Genetics Corporation since December 11, 2015 and also served as its Chief Executive Officer since March 24, 2016 until May 4, 2021. Elliott had been the Chief Scientific Officer at Ambry Genetics Corporation since September 24, 2015 until December 11, 2015. He served as Interim Chief Operating Officer at Ambry Genetics Corporation from December 11, 2015 to January 12, 2018. Elliott conducted his postdoctoral training in the cancer stem cell department at the Novartis Institute for Functional Genomics in San Diego, CA., where he studied potential drug targets for chemotherapeutic resistance and identified the first mitochondrial ABC transporter implicated in cancer drug resistance. Elliott served as a Vice President of Research and Development at Ambry Genetics Corporation and served as its Director of Research & Development and Director of Genomic Services.Elliott received his Bachelor of Science degree in Biology from Franklin and Marshall College and went on to do his Genetics Ph.D. training at the Sidney Kimmel Cancer Center at Thomas Jefferson University and Johns Hopkins University School of Medicine.

Positions